Russell Investments Group
XENE icon

Russell Investments Group’s Xenon Pharmaceuticals XENE Stock Holding History

Russell Investments Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.25M Buy
153,227
+23,828
+18% +$1.32M 0.01% 1123
2026
Q1 		$7.52M Buy
129,399
+43,179
+50% +$1.99M 0.01% 1107
2025
Q4 		$3.86M Buy
86,220
+16,328
+23% +$686K ﹤0.01% 1476
2025
Q3 		$2.81M Buy
69,892
+17,756
+34% +$625K ﹤0.01% 1677
2025
Q2 		$1.63M Sell
52,136
-23,205
-31% -$757K ﹤0.01% 1824
2025
Q1 		$2.53M Sell
75,341
-138,355
-65% -$5.25M ﹤0.01% 1556
2024
Q4 		$8.38M Sell
213,696
-9,918
-4% -$410K 0.01% 898
2024
Q3 		$8.8M Buy
223,614
+60,764
+37% +$2.45M 0.01% 890
2024
Q2 		$6.35M Sell
162,850
-15,249
-9% -$610K 0.01% 1037
2024
Q1 		$7.67M Buy
178,099
+3,813
+2% +$175K 0.01% 959
2023
Q4 		$8.03M Buy
174,286
+4,898
+3% +$173K 0.01% 896
2023
Q3 		$5.79M Buy
169,388
+18,932
+13% +$708K 0.01% 1015
2023
Q2 		$5.79M Buy
150,456
+65,098
+76% +$2.59M 0.01% 1031
2023
Q1 		$3.05M Buy
85,358
+1,028
+1% +$38K 0.01% 1341
2022
Q4 		$3.33M Sell
84,330
-14,744
-15% -$537K 0.01% 1303
2022
Q3 		$3.58M Sell
99,074
-8,825
-8% -$317K 0.01% 1245
2022
Q2 		$3.28M Buy
107,899
+33,980
+46% +$1.03M 0.01% 1315
2022
Q1 		$2.26M Buy
73,919
+21,748
+42% +$651K ﹤0.01% 1578
2021
Q4 		$1.63M Buy
+52,171
New +$1.56M ﹤0.01% 1909
2020
Q1 		– Sell
-24,460
Closed -$320K – 3155
2019
Q4 		$320K Sell
24,460
-12,544
-34% -$132K ﹤0.01% 2556
2019
Q3 		$332K Sell
37,004
-46,276
-56% -$438K ﹤0.01% 2432
2019
Q2 		$821K Buy
83,280
+78,679
+1,710% +$753K ﹤0.01% 2066
2019
Q1 		$47K Buy
4,601
+389
+9% +$3.3K ﹤0.01% 2806
2018
Q4 		$27K Buy
+4,212
New +$37.4K ﹤0.01% 2849

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Russell Investments Group's XENE Position: Q2 2026 in Review

Russell Investments Group increased its Xenon Pharmaceuticals (XENE) stake by 18% in Q2 2026, buying an estimated $1.32M and bringing the position to 153,227 shares worth $9.25M. The position accounts for 0.01% of the portfolio, ranked #1123.

Russell Investments Group first reported a position in XENE in Q4 2018 and has held it in 24 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Russell Investments Group held 153,227 shares of Xenon Pharmaceuticals worth $9.25M as of Q2 2026.
  • Russell Investments Group bought 23,828 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.32M.
  • Xenon Pharmaceuticals made up 0.01% of Russell Investments Group's portfolio in Q2 2026, its #1123 holding.
  • Russell Investments Group first reported a position in Xenon Pharmaceuticals in Q4 2018 and has held it in 24 quarters since.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.